Journal
BLOOD
Volume 132, Issue 10, Pages 1007-1012Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2018-03-828269
Keywords
-
Categories
Funding
- Astra-Zeneca
- Novartis
- AbbVie
- Genentech
- Eli Lilly
- Cellectis
- Calithera
- Stemline
- Threshold
- Flexus Biosciences
Ask authors/readers for more resources
B-cell lymphoma 2 (BCL-2) was discovered at the breakpoint of the t(14; 18) in follicular lymphoma >30 years ago. Although inhibition of BCL-2 first proved valuable in lymphoid malignancies, clinical progress in myeloid malignancies lagged. Here, we summarize the basic biology and preclinical results that spurred clinical BCL-2 inhibition in acute myeloid leukemia (AML). Response rates and toxicity for venetoclax in combination with standard AML agents, such as azacitidine, decitabine, and low-dose cytarabine, compare favorably with conventional induction chemotherapy. Durability of response requires further study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available